44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement38th Annual Miami Breast Cancer Conference® - Abstracts
Volume 35
Issue suppl 1
Pages: 24

Michael M. Gaschler, PhD1; Qi Fu, PhD1; Debanjali Mitra2; Samantha Kurosky2

1Kantar, New York, NY

2Pfizer Inc, New York, NY

Background

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) are a recommended standard of care for many first-line (1L) hormone receptor–positive, HER2-negative (HR+/HER2-) advanced/metastatic breast cancers (mBC). Yet, substantial use of 1L ET monotherapy and chemotherapy (CT) regimens have been observed. This study sought to understand United States (US) physician perspectives on clinical, economic, and institutional factors that inform 1L mBC regimen selection.

Methods

We recruited 23 US oncologists treating patients with HR+/HER2- mBC for 45-minute, qualitative, one-on-one telephone interviews. Physicians were selected based on self-reported 1L patient volume and prescribing behaviors. Self-reported 1L prescribing behavior was used to sort physicians into 1 of 3 cohorts: “high CDK4/6i prescribers,” “high ET monotherapy prescribers,” or “high CT prescribers.” Physicians were not aware of their cohort, and all interviews were conducted based on the same discussion guide. Discussions were coded and analyzed using a thematic approach with the MAXQDA (v12.0) software.

Results

All cohorts reported high use of 1L CDK4/6i plus ET regimens and ranked clinical data as the primary driver of regimen selection. However, each cohort identified unique treatment-level, patient-level, and nonclinical factors that influenced 1L regimen choice. The high CDK4/6i cohort (n = 5) considered CDK4/6i plus ET regimens to be appropriate for nearly all 1L patients, seldom relying on nonclinical factors to guide treatment. The high ET-monotherapy cohort (n = 10) valued a perceived balance of efficacy and tolerability achieved with ET-monotherapy regimens, particularly for elderly patients. This cohort reported their patients faced affordability challenges with CDK4/6i, describing greater difficulties resolving cost issues. High CT prescribers (n = 8) valued a perceived fast response and high compliance rate with CT. High CT prescribers also indicated patient comorbidities influenced regimen selection.

Conclusions

All cohorts recognized CDK4/6i plus ET regimens as the preferred standard of care for most patients, but perceptions of the appropriateness of 1L regimens varied across cohorts. Continued demonstration of CDK4/6i plus ET safety and effectiveness across broader patient populations in real-world settings may provide the additional evidence needed to support appropriate 1L treatment selection.

Articles in this issue

1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
1 The Tolerance of CREATE-X Capecitabine Dosing in a United States TNBC Patient Population
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
6 Survival Benefit of Eribulin, But Not Capecitabine, for Metastatic Breast Cancer Is Associated With Baseline Absolute Lymphocyte Count in Peripheral Blood
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
7 Evaluation of the 21-Gene Recurrence Score (RS) Assay Results Following Successful Intraoperative Radiation Therapy (IORT) Treatment of Patients With Early-Stage Breast Cancer
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
8 Concordance of Tumor Response with Eribulin Use in Real-World Clinical Practice
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
13 Real-world Treatment Patterns and Tumor Response of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
14 Real-World (RW) Treatment Patterns and Clinical Effectiveness of Palbociclib (PAL) Plus an Aromatase Inhibitor (AI) as First-Line Therapy in Advanced/ Metastatic Breast Cancer (A/MBC): Analysis From Syapse Learning Health Network
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
25 A Retrospective Cohort Study of Demographic, Clinical, and Treatment Characteristics of Patients With Metastatic Breast Cancer Who Have Received PARP Inhibitors
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
28 Primary Outcome Analysis of Invasive Disease-Free Survival for monarchE: Abemaciclib Plus Adjuvant Endocrine Therapy for High-Risk Early Breast Cancer
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
30 Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Early- Stage Breast Cancer (ESBC) Receiving Docetaxel and Cyclophosphamide
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
35 Decreased Epithelial Mesenchymal Transition Process After AGTR-1 Gene Edition By Crispr/Cas9, Losartan, and PARP Inhibitor Treatment In Breast Cancer Cell Line
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
37 Treatment Outcomes Using Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer in African American and Hispanic Women
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
42 The United States Retrospective Claims Database Analysis of Demographic, Clinical, and Treatment Characteristics of Metastatic Breast Cancer Patients receiving Olaparib
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
43 Lobular Cancer Responsiveness to Chemotherapy Is Equivalent to That of Ductal Cancer With Similar Genomic Profiles: An NCDB Analysis
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
44 Drivers of Oncologist Treatment Selection in HR+/HER2- Metastatic Breast Cancer
45 Neoadjuvant Chemotherapy Use in Elderly Patients
45 Neoadjuvant Chemotherapy Use in Elderly Patients
Related Content